Roche’s decision to launch a new global Phase 3 trial of Elevidys, aimed at supporting a fresh approval push in Europe, puts Sarepta Therapeutics (SRPT) back in focus for investors watching Duchenne gene therapy.

The fresh Elevidys trial comes as Sarepta’s share price has shown a 25.6% 1 month gain to US$21.55, yet the 1 year total shareholder return of about 60% decline highlights that long term holders have faced significant volatility and pressure.

If this Duchenne gene therapy news has you thinking about where else capital could work in healthcare, it may be worth scanning other specialised opportunities through our 35 healthcare AI stocks

With the shares up 25.6% over the past month but still showing about a 60% 1 year total return decline, the key question is whether Sarepta now offers mispriced upside or if the market already reflects any future growth.

Most Popular Narrative: 50% Undervalued

At a last close of $21.55 versus a narrative fair value of $21.65, Sarepta looks close to that estimate on price yet still screens as materially undervalued on modeled cash flows.

The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.

Want to see what sits behind that wide range of outcomes? The narrative focuses on a profit swing, a shifting revenue profile and a premium future earnings multiple.

Result: Fair Value of $21.65 (UNDERVALUED)

However, there are still real pressure points, including safety scrutiny around ELEVIDYS and high research spending that could challenge the profit swing this narrative assumes.

Next Steps

With sentiment clearly mixed and both risks and rewards in play, it makes sense to look at the data yourself and move quickly to shape your own view by weighing the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If this story has you rethinking where your next dollar should go, use the Simply Wall Street Screener to line up fresh opportunities before others spot them.

• Target potential bargains by checking companies that combine quality fundamentals with appealing valuations through the 59 high quality undervalued stocks.
• Prioritise resilience by reviewing businesses that feature robust finances using the solid balance sheet and fundamentals stocks screener (42 results).
• Hunt for lesser known opportunities by scanning the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.